All
CLL Survivors Worried About Life Expectancy, Quality of Life
December 25th 2017While patients with chronic lymphocytic leukemia (CLL) tend to have long life expectancies, with many prescribed to a “watch-and-wait” approach, a recent study by the Cancer Support Community (CSC) found that more than half of patients living with the disease reported that having CLL affects their viewpoints regarding their life expectancy.
Four-Drug Combination Improves NSCLC Outcomes
December 24th 2017A four-drug combination, including Tecentriq (atezolizumab), Avastin (bevacizumab), carboplatin and paclitaxel, delayed progression or death by 38 percent in patients with advanced non-squamous non–small cell lung cancer (NSCLC), compared to those who were treated with Avastin alone.
Childhood Cancer Survivors at Increased Risk for High Blood Pressure
December 23rd 2017Approximately 420,000 Americans are adult survivors of childhood cancer, and these individuals may be twice as likely to have high blood pressure, also known as hypertension, according to researchers at St. Jude Children’s Research Hospital.
Immunotherapy Is Entering the Stage 3 Lung Cancer Landscape
December 22nd 2017Imfinzi (durvalumab), a PD-L1 inhibitor, is being reviewed for a supplemental biologics license application (sBLA) by the Food and Drug Administration (FDA) for the treatment of patients with stage 3, unresectable non-small cell lung cancer (NSCLC). The sBLA is in light of positive progression-free survival (PFS) results from the phase 3 PACIFIC trial.
Tafinlar Plus Mekinist Combination Granted Priority Review for Melanoma Treatment
December 22nd 2017The Food and Drug Administration (FDA) has granted a priority review to a supplemental new drug application (sNDA) for the use of Tafinlar (dabrafenib) combined with Mekinist (trametinib) as an adjuvant treatment for patients with BRAFV600E– or V600K–positive stage 3 melanoma following complete resection.
Apalutamide Granted Priority Review for Castration-Resistant Prostate Cancer
December 21st 2017The FDA has granted a priority review to a new drug application (NDA) for apalutamide (ARN-509) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.
Blue Faery Helps Patients Spread Their Wings After Liver Cancer Diagnosis
December 21st 2017Blue Faery, the Adrienne Wilson Liver Cancer Association, is a nonprofit corporation founded in 2002, with the intent to prevent, treat and cure primary liver cancer – particularly HCC – through research, education and advocacy. Its name, inspired by Adrienne, has a unique background.
Perjeta Combination Granted FDA Approval for Breast Cancer
December 21st 2017The FDA has approved Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy as an adjuvant treatment for patients with HER2-positive early breast cancer at high risk for recurrence, based on findings from the APHINITY trial.
Optune Combination Improves Survival in Glioblastoma
December 21st 2017Optune is a method of treatment where adhesive patches are applied to the patient’s scalp. The patch transductors deliver low-intensity electric fields – called Tumor Treating Fields – that stop the growth and division of GBM cells.
Complications of Cancer: Nausea
December 20th 2017Of every complication caused from cancer and its treatments, nausea has been the worst for my sister. It has caused pain, discomfort and was the number one reason she returned to the emergency room. No matter what medications were dosed, whether it was orally or by IV, or how much they gave to her, so often, nothing ever seemed to work.